Healthcare provider profile · identity verified

Khaled Elias, MD

Family Practice · OAKLAND PARK, FL · NPI 1366070385

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	378	157
Gabapentin	Gabapentin	355	120
Amlodipine Besylate	Amlodipine Besylate	290	126
Tizanidine Hcl	Tizanidine Hcl	269	144
Losartan Potassium	Losartan Potassium	248	91
Albuterol Sulfate Hfa	Albuterol Sulfate	237	74
Lisinopril	Lisinopril	225	90
Diclofenac Sodium	Diclofenac Sodium	200	120
Fluticasone Propionate	Fluticasone Propionate	200	114
Rosuvastatin Calcium	Rosuvastatin Calcium	181	77
Pantoprazole Sodium	Pantoprazole Sodium	167	94
Metformin Hcl	Metformin Hcl	157	67
Levothyroxine Sodium	Levothyroxine Sodium	149	54
Tamsulosin Hcl	Tamsulosin Hcl	145	64
Triamcinolone Acetonide	Triamcinolone Acetonide	142	97
Metoprolol Succinate	Metoprolol Succinate	121	53
Trazodone Hcl	Trazodone Hcl	121	47
Furosemide	Furosemide	115	58
Metoprolol Tartrate	Metoprolol Tartrate	103	43
Eliquis	Apixaban	102	27
Glipizide	Glipizide	102	40
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	88	30
Nifedipine Er	Nifedipine	82	35
Omeprazole	Omeprazole	81	44
Azithromycin	Azithromycin	79	57
Carvedilol	Carvedilol	74	29
Methylprednisolone	Methylprednisolone	70	47
Duloxetine Hcl	Duloxetine Hcl	69	29
Warfarin Sodium	Warfarin Sodium	67	12
Ibuprofen	Ibuprofen	66	30
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	63	21
Finasteride	Finasteride	61	26
Hydrochlorothiazide	Hydrochlorothiazide	59	23
Alendronate Sodium	Alendronate Sodium	58	14
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	55	35
Ondansetron Odt	Ondansetron	55	37
Zolpidem Tartrate	Zolpidem Tartrate	54	16
Clopidogrel	Clopidogrel Bisulfate	53	26
Hydralazine Hcl	Hydralazine Hcl	53	20
Tramadol Hcl	Tramadol Hcl	52	20
Bumetanide	Bumetanide	49	22
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	48	38
Ozempic	Semaglutide	47	11
Simvastatin	Simvastatin	45	21
Metformin Hcl Er	Metformin Hcl	43	17
Famotidine	Famotidine	42	26
Montelukast Sodium	Montelukast Sodium	42	19
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	41	34
Memantine Hcl	Memantine Hcl	41	16
Hydroxyzine Hcl	Hydroxyzine Hcl	40	20
Clobetasol Propionate	Clobetasol Propionate	39	35
Clonidine Hcl	Clonidine Hcl	39	17
Pregabalin	Pregabalin	39	13
Pioglitazone Hcl	Pioglitazone Hcl	38	17
Sertraline Hcl	Sertraline Hcl	38	17
Sildenafil Citrate	Sildenafil Citrate	35	11
Ketoconazole	Ketoconazole	34	14
Pravastatin Sodium	Pravastatin Sodium	33	11
Alprazolam	Alprazolam	32	11
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	31	15
Mirtazapine	Mirtazapine	31	21
Allopurinol	Allopurinol	30	suppressed
Mounjaro	Tirzepatide	30	suppressed
Baclofen	Baclofen	28	suppressed
Atenolol	Atenolol	27	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	27	13
Labetalol Hcl	Labetalol Hcl	27	11
Prednisone	Prednisone	27	12
Diazepam	Diazepam	24	suppressed
Celecoxib	Celecoxib	23	16
Citalopram Hbr	Citalopram Hydrobromide	23	12
Meclizine Hcl	Meclizine Hcl	23	16
Polymyxin B Sul-Trimethoprim	Polymyxin B Sulf/Trimethoprim	23	17
Biktarvy	Bictegrav/Emtricit/Tenofov Ala	22	suppressed
Breo Ellipta	Fluticasone/Vilanterol	22	suppressed
Descovy	Emtricitabine/Tenofov Alafenam	22	suppressed
Donepezil Hcl	Donepezil Hcl	21	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	21	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	21	suppressed
Lorazepam	Lorazepam	21	suppressed
Testosterone Cypionate	Testosterone Cypionate	21	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	20	13
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	20	suppressed
Ropinirole Hcl	Ropinirole Hcl	20	suppressed
Latanoprost	Latanoprost	19	suppressed
Novolog Flexpen	Insulin Aspart	19	suppressed
Potassium Chloride	Potassium Chloride	19	15
Clindamycin Hcl	Clindamycin Hcl	18	17
Clonazepam	Clonazepam	18	suppressed
Temazepam	Temazepam	18	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	17	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	17	suppressed
Symtuza	Darunavir/Cob/Emtri/Tenof Alaf	17	suppressed
Levofloxacin	Levofloxacin	16	13
Trulicity	Dulaglutide	16	suppressed
Dovato	Dolutegravir Sodium/Lamivudine	15	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	15	12
Juluca	Dolutegravir/Rilpivirine	15	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	15	suppressed
Testosterone	Testosterone	15	suppressed
Acyclovir	Acyclovir	14	suppressed
Nystatin	Nystatin	14	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	14	suppressed
Carbamazepine Er	Carbamazepine	13	suppressed
Valsartan	Valsartan	13	suppressed
Bupropion Xl	Bupropion Hcl	12	suppressed
Januvia	Sitagliptin Phosphate	12	suppressed
Lactulose	Lactulose	12	suppressed
Spironolactone	Spironolactone	12	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	12	suppressed
Linzess	Linaclotide	11	suppressed
Loperamide	Loperamide Hcl	11	suppressed
Meloxicam	Meloxicam	11	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	11	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	11	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error